U.S. Capital Wealth Advisors LLC increased its stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 213.9% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 15,484 shares of the company's stock after acquiring an additional 10,551 shares during the period. U.S. Capital Wealth Advisors LLC's holdings in AstraZeneca were worth $1,138,000 as of its most recent filing with the SEC.
Other hedge funds have also made changes to their positions in the company. Capital International Investors grew its holdings in AstraZeneca by 1.9% in the 4th quarter. Capital International Investors now owns 37,507,159 shares of the company's stock valued at $2,457,706,000 after buying an additional 686,008 shares during the last quarter. Bank of America Corp DE grew its holdings in AstraZeneca by 189.3% in the 4th quarter. Bank of America Corp DE now owns 24,026,966 shares of the company's stock valued at $1,574,247,000 after buying an additional 15,722,197 shares during the last quarter. Franklin Resources Inc. grew its holdings in AstraZeneca by 1.9% in the 4th quarter. Franklin Resources Inc. now owns 19,480,569 shares of the company's stock valued at $1,276,367,000 after buying an additional 357,894 shares during the last quarter. Sanders Capital LLC grew its holdings in AstraZeneca by 1.4% in the 4th quarter. Sanders Capital LLC now owns 15,186,692 shares of the company's stock valued at $995,032,000 after buying an additional 212,301 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in AstraZeneca by 13.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 5,322,388 shares of the company's stock valued at $348,730,000 after buying an additional 636,537 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company's stock.
AstraZeneca Stock Performance
Shares of AZN stock traded down $0.68 during mid-day trading on Friday, reaching $71.13. The stock had a trading volume of 2,729,851 shares, compared to its average volume of 5,270,319. The firm's 50 day simple moving average is $70.72 and its 200 day simple moving average is $70.78. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68. The firm has a market cap of $220.60 billion, a PE ratio of 28.57, a P/E/G ratio of 1.32 and a beta of 0.37.
AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The company had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. During the same quarter last year, the company earned $2.06 EPS. The company's quarterly revenue was up 7.2% on a year-over-year basis. On average, analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current year.
Wall Street Analyst Weigh In
AZN has been the topic of a number of research analyst reports. Berenberg Bank set a $97.00 target price on AstraZeneca in a report on Wednesday. BNP Paribas initiated coverage on AstraZeneca in a report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, AstraZeneca presently has a consensus rating of "Moderate Buy" and a consensus price target of $89.00.
Read Our Latest Stock Analysis on AZN
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Stories
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
